Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q2 FY23 results · Jul–Sep 2022
Lincoln Pharmaceuticals reported revenue from operations of ₹140.61 crore and net profit of ₹23.71 crore for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 140.61 | — | — | 123.47 | +13.9% |
| Other income | 5.72 | — | — | 6.49 | −11.9% |
| Total income | 146.33 | — | — | 129.97 | +12.6% |
| Profit before tax | 32.06 | — | — | 20.93 | +53.2% |
| Net profit for the period | 23.71 | — | — | 15.01 | +58.0% |
| EPS, basic (₹) | 11.84 | — | — | 7.49 | +58.1% |
| Net margin (%) | 16.9 | — | 12.2 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 140.61 | 125.64 | +11.9% | 123.47 | +13.9% |
| Other income | 5.69 | 3.77 | +50.7% | 6.49 | −12.5% |
| Total income | 146.30 | 129.41 | +13.0% | 129.97 | +12.6% |
| Profit before tax | 32.03 | 30.24 | +5.9% | 20.93 | +53.1% |
| Net profit for the period | 23.71 | 22.88 | +3.6% | 15.01 | +58.0% |
| EPS, basic (₹) | 11.84 | 11.44 | +3.5% | 7.49 | +58.1% |
| Net margin (%) | 16.9 | 18.2 | 12.2 |
Consolidated
- Filed with BSE
- 22 Nov 2022, 16:14 IST
- Board meeting
- 10 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 Nov 2022, 16:14 IST
- Board meeting
- 10 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE